COVID-19 off-label uses of medicines: the role of civil liability and regulation

Andrea Parziale*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Downloads (Pure)

Abstract

Physicians can prescribe medicines for different indications than the tested and authorised ones. Such 'off-label' uses expand therapeutic options but also create uncertainties. The COVID-19 pandemic triggered new off-label uses and, despite issues being reported in the literature, these have not resulted in substantial personal injury litigation in the EU. Against this backdrop, this article argues that civil liability plays, in fact, a limited role in off-label uses. In particular, civil liability may incentivise health actors to follow and react to the development of the evidence basis for off-label uses. However, it is ultimately unable to incentivise the conduct of additional research on off-label uses. This is problematic, as off-label research is key to protecting patients and is recommended by international medical ethics. The article concludes by critically discussing proposed mechanisms to incentivise off-label research. It argues that extending civil liability for unknown risks may have undesired effects on insurability and innovation, and most regulatory proposals seem ineffective. Building on the 2014 Italian reform of off-label uses, the article proposes the establishment of a fund financed by mandatory contributions from the industry, which should be used by pharmaceutical regulators to promote off-label research and develop guidelines for prescribers.
Original languageEnglish
Pages (from-to)669-686
Number of pages18
JournalGeneva Papers on Risk and Insurance - Issues and Practice
Volume48
Early online date1 May 2023
DOIs
Publication statusPublished - Jul 2023

Keywords

  • off-label uses of medicines
  • COVID-19
  • civil liability
  • pharmaceutical regulation
  • research incentives
  • EU
  • drug-use
  • compassionate use
  • European Unioin
  • framework

Fingerprint

Dive into the research topics of 'COVID-19 off-label uses of medicines: the role of civil liability and regulation'. Together they form a unique fingerprint.

Cite this